Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost - PubMed (original) (raw)
Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost
M W Climo et al. Ann Intern Med. 1998.
Abstract
Background: Widespread antibiotic use has been associated with increases in both bacterial resistance and nosocomial infection.
Objective: To characterize the impact of hospital-wide clindamycin restriction on the incidence of Clostridium difficile-associated diarrhea and on antimicrobial prescribing practices.
Design: Prospective, observational cohort study.
Setting: University-affiliated Veterans Affairs Medical Center.
Patients: Hospitalized patients with symptomatic diarrhea.
Measurements: Clinical data on individual patients and data on antibiotic use were obtained from hospital pharmacy records. Hospital-wide use of antimicrobial agents was monitored. Isolates of C. difficile underwent antimicrobial susceptibility testing and molecular typing.
Results: An outbreak of C. difficile-associated diarrhea was caused by a clonal isolate of clindamycin-resistant C. difficile and was associated with increased use of clindamycin. Hospital-wide requirement of approval by an infectious disease consultant of clindamycin use led to an overall reduction in clindamycin use, a sustained reduction in the mean number of cases of C. difficile-associated diarrhea (11.5 cases/month compared with 3.33 cases/month; P < 0.001), and an increase in clindamycin susceptibility among C. difficile isolates (9% compared with 61%; P < 0.001). A parallel increase was noted in the use of and costs associated with other antibiotics with antianaerobic activity, including cefotetan, ticarcillin-clavulanate, and imipenem-cilastin. The hospital realized overall cost savings as a result of the decreased incidence of C. difficile-associated diarrhea.
Conclusions: Hospital formulary restriction of clindamycin is an effective way to decrease the number of infections due to C. difficile. It can also lead to a return in clindamycin susceptibility among isolates and can effect cost savings to the hospital.
Similar articles
- Clindamycin formulary restriction lowers costs, antimicrobial resistance.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 1998 Aug 1;55(15):1552. doi: 10.1093/ajhp/55.15.1552. Am J Health Syst Pharm. 1998. PMID: 9706176 No abstract available. - Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use.
Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Pear SM, et al. Ann Intern Med. 1994 Feb 15;120(4):272-7. doi: 10.7326/0003-4819-120-4-199402150-00003. Ann Intern Med. 1994. PMID: 8080497 - Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea.
Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Kyne L, et al. Infect Control Hosp Epidemiol. 2002 Nov;23(11):653-9. doi: 10.1086/501989. Infect Control Hosp Epidemiol. 2002. PMID: 12452292 - Recent changes in Clostridium difficile infection.
Silva Júnior M. Silva Júnior M. Einstein (Sao Paulo). 2012 Jan-Mar;10(1):105-9. doi: 10.1590/s1679-45082012000100023. Einstein (Sao Paulo). 2012. PMID: 23045838 Review. - Antimicrobial stewardship and Clostridium difficile-associated diarrhea.
Piacenti FJ, Leuthner KD. Piacenti FJ, et al. J Pharm Pract. 2013 Oct;26(5):506-13. doi: 10.1177/0897190013499528. Epub 2013 Aug 14. J Pharm Pract. 2013. PMID: 23946208 Review.
Cited by
- Clostridium difficile infection: a surgical disease in evolution.
Hermsen JL, Dobrescu C, Kudsk KA. Hermsen JL, et al. J Gastrointest Surg. 2008 Sep;12(9):1512-7. doi: 10.1007/s11605-008-0569-9. Epub 2008 Jul 9. J Gastrointest Surg. 2008. PMID: 18612709 - Clostridium difficile infection in the community: are proton pump inhibitors to blame?
Freedberg DE, Abrams JA. Freedberg DE, et al. World J Gastroenterol. 2013 Oct 28;19(40):6710-3. doi: 10.3748/wjg.v19.i40.6710. World J Gastroenterol. 2013. PMID: 24187445 Free PMC article. - Detection of Clostridium difficile infection clusters, using the temporal scan statistic, in a community hospital in southern Ontario, Canada, 2006-2011.
Faires MC, Pearl DL, Ciccotelli WA, Berke O, Reid-Smith RJ, Weese JS. Faires MC, et al. BMC Infect Dis. 2014 May 12;14:254. doi: 10.1186/1471-2334-14-254. BMC Infect Dis. 2014. PMID: 24885351 Free PMC article. - Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome.
Silveira CB, Cobián-Güemes AG, Uranga C, Baker JL, Edlund A, Rohwer F, Conrad D. Silveira CB, et al. Int J Mol Sci. 2021 Nov 7;22(21):12050. doi: 10.3390/ijms222112050. Int J Mol Sci. 2021. PMID: 34769481 Free PMC article. - Economic evaluation of interventions designed to reduce Clostridium difficile infection.
Brain D, Yakob L, Barnett A, Riley T, Clements A, Halton K, Graves N. Brain D, et al. PLoS One. 2018 Jan 3;13(1):e0190093. doi: 10.1371/journal.pone.0190093. eCollection 2018. PLoS One. 2018. PMID: 29298322 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical